804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected…
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa…
EDINBURGH and CAMBRIDGE, United Kingdom, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, continues…
ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage…
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation…
Trial participants with Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) could benefit from this joint effort to…
Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their…
-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology ---- PoNS system and mouthpiece will be…
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a…